Doximity Announces Fiscal 2025 Second Quarter Financial Results

Author's Avatar
Nov 07, 2024

Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 second quarter ended September 30, 2024.

“Our clinical workflow tools saw record use in Q2 with over 600,000 unique active prescribers,” said Jeff Tangney, co-founder and CEO of Doximity. “We’re proud to help physicians save time, so they can provide better care for their patients.”

Fiscal 2025 Second Quarter Financial Highlights

All comparisons, unless otherwise noted, are to the three months ended September 30, 2023.

  • Revenue: Revenue of $136.8 million, versus $113.6 million, an increase of 20% year-over-year.
  • Net income and non-GAAP net income: Net income of $44.2 million, versus $30.6 million, representing a margin of 32.3%, versus 26.9%. Non-GAAP net income of $61.1 million, versus $45.6 million, representing a margin of 44.7%, versus 40.1%.
  • Adjusted EBITDA: Adjusted EBITDA of $76.1 million, versus $54.2 million, an increase of 41% year-over-year, representing adjusted EBITDA margins of 55.7%, versus 47.7%.
  • Diluted net income per share and non-GAAP diluted net income per share: Diluted net income per share was $0.22, versus $0.15, while non-GAAP diluted net income per share was $0.30, versus $0.22.
  • Operating cash flow and free cash flow: Operating cash flow of $68.3 million, versus $12.9 million, an increase of 430% year-over-year, and free cash flow of $66.8 million, versus $11.6 million, an increase of 475% year-over-year.

Financial Outlook

Doximity is providing guidance for its fiscal third quarter ending December 31, 2024 as follows:

  • Revenue between $152 million and $153 million.
  • Adjusted EBITDA between $83 million and $84 million.

Doximity is updating guidance for its fiscal year ending March 31, 2025 as follows:

  • Revenue between $535 million and $540 million.
  • Adjusted EBITDA between $274 million and $279 million.

Conference Call Information

Doximity posted prepared remarks on its investor relations website at https://investors.doximity.com. Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com. The archived webcast will be available on the Company’s Investor Relations page shortly after the call.

About Doximity

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better care for their patients.

Forward-Looking Statements

Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including (i) the timing and scope of anticipated stock repurchases; (ii) the impact of uncertainty in the current economic environment and macroeconomic uncertainty; (iii) our ability to retain existing members or add new members to our platform and maintain or grow their engagement with our platform; (iv) our ability to attract new customers or retain existing customers; (v) the impact of our prioritization of our members’ interests; (vi) breaches in our security measures or unauthorized access to members’ data; (vii) our ability to maintain or manage our growth, and other risks and factors that are beyond our control including, without limitation, those set forth in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024 and as may be updated in any subsequent Quarterly Reports on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management’s beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

DOXIMITY, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

September 30, 2024

March 31, 2024

Assets

Current assets:

Cash and cash equivalents

$

184,248

$

96,785

Marketable securities

621,310

666,115

Accounts receivable, net

124,793

101,332

Prepaid expenses and other current assets

27,361

48,709

Total current assets

957,712

912,941

Property and equipment, net

12,818

12,318

Deferred income tax assets

43,761

45,068

Operating lease right-of-use assets

9,774

12,332

Intangible assets, net

25,195

27,317

Goodwill

67,940

67,940

Other assets

1,316

1,458

Total assets

$

1,118,516

$

1,079,374

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$

2,770

$

2,253

Accrued expenses and other current liabilities

33,540

43,703

Deferred revenue, current

93,751

99,145

Operating lease liabilities, current

2,222

2,149

Total current liabilities

132,283

147,250

Deferred revenue, non-current

148

211

Operating lease liabilities, non-current

11,269

12,397

Contingent earn-out consideration liability, non-current

5,469

10,895

Other liabilities, non-current

8,151

7,224

Total liabilities

157,320

177,977

Stockholders' Equity

Preferred stock

—

—

Common stock

187

187

Additional paid-in capital

863,113

823,885

Accumulated other comprehensive income (loss)

2,676

(2,664

)

Retained earnings

95,220

79,989

Total stockholders’ equity

961,196

901,397

Total liabilities and stockholders’ equity

$

1,118,516

$

1,079,374

DOXIMITY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

Three Months Ended September 30,

Six Months Ended September 30,

2024

2023

2024

2023

Revenue

$

136,832

$

113,612

$

263,508

$

222,081

Cost of revenue(1)

13,676

12,759

27,226

25,912

Gross profit

123,156

100,853

236,282

196,169

Operating expenses(1):

Research and development

23,240

19,958

45,814

41,889

Sales and marketing

34,367

30,201

69,611

64,656

General and administrative

10,103

8,966

19,358

18,213

Restructuring and impairment charge

2,304

7,936

2,304

7,936

Total operating expenses

70,014

67,061

137,087

132,694

Income from operations

53,142

33,792

99,195

63,475

Other income, net

9,029

5,903

16,145

10,742

Income before income taxes

62,171

39,695

115,340

74,217

Provision for income taxes

18,017

9,093

29,809

15,209

Net income

$

44,154

$

30,602

$

85,531

$

59,008

Net income per share attributable to Class A and Class B common stockholders:

Basic

$

0.24

$

0.16

$

0.46

$

0.30

Diluted

$

0.22

$

0.15

$

0.43

$

0.28

Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

Basic

186,252

193,112

185,933

193,813

Diluted

200,407

209,014

199,818

210,681

(1) Costs and expenses include stock-based compensation expense as follows (in thousands):

Three Months Ended September 30,

Six Months Ended September 30,

2024

2023

2024

2023

Cost of revenue

$

2,661

$

2,278

$

5,555

$

4,739

Research and development

5,447

2,538

10,131

5,794

Sales and marketing

6,808

2,697

13,394

8,692

General and administrative

2,952

2,288

5,878

4,577

Restructuring

—

3,646

—

3,646

Total stock-based compensation expense

$

17,868

$

13,447

$

34,958

$

27,448

DOXIMITY, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

Three Months Ended September 30,

Six Months Ended September 30,

2024

2023

2024

2023

Cash flows from operating activities

Net income

$

44,154

$

30,602

$

85,531

$

59,008

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

2,613

2,604

5,175

5,208

Deferred income taxes

204

—

204

—

Stock-based compensation, net of amounts capitalized

17,868

13,447

34,958

27,448

Non-cash lease expense

470

540

951

1,077

Accretion of discount on marketable securities, net

(3,008

)

(1,495

)

(5,368

)

(1,794

)

Amortization of deferred contract costs

2,033

2,063

4,759

4,730

Impairment of long-lived assets

2,304

—

2,304

—

Other

414

6

(122

)

127

Changes in operating assets and liabilities:

Accounts receivable

(4,106

)

(4,388

)

(23,478

)

9,644

Prepaid expenses and other assets

9,488

(13,093

)

19,948

(10,504

)

Deferred contract costs

(1,785

)

(1,238

)

(3,216

)

(2,448

)

Accounts payable, accrued expenses and other liabilities

7,396

(8,740

)

(5,546

)

(8,063

)

Deferred revenue

(9,161

)

(6,831

)

(5,457

)

(13,753

)

Operating lease liabilities

(538

)

(579

)

(1,054

)

(582

)

Net cash provided by operating activities

68,346

12,898

109,589

70,098

Cash flows from investing activities

Purchases of property and equipment

—

(41

)

—

(111

)

Internal-use software development costs

(1,543

)

(1,238

)

(3,247

)

(2,732

)

Purchases of marketable securities

(197,395

)

(144,942

)

(367,808

)

(180,226

)

Maturities of marketable securities

215,855

96,119

417,913

212,768

Sales of marketable securities

7,241

—

7,241

37,525

Net cash provided by (used in) investing activities

24,158

(50,102

)

54,099

67,224

Cash flows from financing activities

Proceeds from issuance of common stock upon exercise of stock options and common stock warrants

7,692

3,933

10,243

7,218

Proceeds from issuance of common stock in connection with the employee stock purchase plan

1,422

1,494

1,422

1,494

Taxes paid related to net share settlement of equity awards

(5,828

)

(2,120

)

(8,222

)

(4,084

)

Repurchase of common stock

(22,984

)

(164,429

)

(74,198

)

(186,184

)

Payment of contingent consideration related to a business combination

—

—

(5,470

)

(5,390

)

Net cash used in financing activities

(19,698

)

(161,122

)

(76,225

)

(186,946

)

Net increase (decrease) in cash and cash equivalents

72,806

(198,326

)

87,463

(49,624

)

Cash and cash equivalents, beginning of period

111,442

306,729

96,785

158,027

Cash and cash equivalents, end of period

$

184,248

$

108,403

$

184,248

$

108,403

Supplemental disclosures of cash flow information

Cash paid for taxes, net of refunds

$

9,078

$

29,438

$

21,985

$

29,438

Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company uses the following non-GAAP measures of financial performance:

  • Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net income per common share: We exclude the effect of stock-based compensation expense, amortization of acquired intangible assets, change in fair value of contingent earn-out consideration liability, and restructuring and impairment charge from non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net income margin are further adjusted for estimated income tax on such adjustments. We calculate income taxes on the adjustments by applying an estimated annual effective tax rate to the adjustments. Non-GAAP basic and diluted net income per common share is non-GAAP net income attributable to common stockholders divided by the weighted average number of shares. For both basic and diluted non-GAAP net income per share, the weighted average shares we use in computing non-GAAP net income per share is equal to our GAAP weighted average shares. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue and non-GAAP net income margin represents non-GAAP net income as a percentage of revenue.
  • Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for stock-based compensation expense, change in fair value of contingent earn-out consideration liability, restructuring and impairment charge, and other income, net. Net income margin represents net income as a percentage of revenue and adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.
  • Free cash flow: We calculate free cash flow as cash flow from operating activities less purchases of property and equipment and internal-use software development costs.

We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.

Key Business Metrics

  • Net revenue retention rate: Net revenue retention rate is calculated by taking the trailing 12-month (“TTM”) subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. For the purposes of this calculation, subscription revenue excludes subscriptions for individuals and small practices and other non-recurring items. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates.
  • Customers with trailing 12-month subscription revenue greater than $500,000: The number of customers with TTM subscription revenue greater than $500,000 is a key indicator of the scale of our business, and is calculated by counting the number of customers that contributed more than $500,000 in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments.

Reconciliation of GAAP to Non-GAAP Financial Measures

The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

Three Months Ended September 30,

Six Months Ended September 30,

2024

2023

2024

2023

(unaudited)

(in thousands, except percentages)

Net income

$

44,154

$

30,602

$

85,531

$

59,008

Adjusted to exclude the following:

Stock-based compensation

17,868

9,801

34,958

23,802

Depreciation and amortization

2,613

2,604

5,175

5,208

Provision for income taxes

18,017

9,093

29,809

15,209

Restructuring and impairment charge

2,304

7,936

2,304

7,936

Change in fair value of contingent earn-out consideration liability

221

47

423

316

Other income, net

(9,029

)

(5,903

)

(16,145

)

(10,742

)

Adjusted EBITDA

$

76,148

$

54,180

$

142,055

$

100,737

Revenue

$

136,832

$

113,612

$

263,508

$

222,081

Net income margin

32.3

%

26.9

%

32.5

%

26.6

%

Adjusted EBITDA margin

55.7

%

47.7

%

53.9

%

45.4

%

Three Months Ended September 30,

Six Months Ended September 30,

2024

2023

2024

2023

(unaudited)

(in thousands)

Net cash provided by operating activities

$

68,346

$

12,898

$

109,589

$

70,098

Purchases of property and equipment

—

(41

)

—

(111

)

Internal-use software development costs

(1,543

)

(1,238

)

(3,247

)

(2,732

)

Free cash flow

$

66,803

$

11,619

$

106,342

$

67,255

Other cash flow components:

Net cash provided by (used in) investing activities

$

24,158

$

(50,102

)

$

54,099

$

67,224

Net cash used in financing activities

$

(19,698

)

$

(161,122

)

$

(76,225

)

$

(186,946

)

Three Months Ended September 30,

Six Months Ended September 30,

2024

2023

2024

2023

(unaudited)

(in thousands, except per share data and percentages)

GAAP cost of revenue

$

13,676

$

12,759

$

27,226

$

25,912

Adjusted to exclude the following:

Stock-based compensation

(2,661

)

(2,278

)

(5,555

)

(4,739

)

Amortization of acquired intangibles

—

(137

)

—

(274

)

Non-GAAP cost of revenue

$

11,015

$

10,344

$

21,671

$

20,899

GAAP gross profit

$

123,156

$

100,853

$

236,282

$

196,169

Adjusted to exclude the following:

Stock-based compensation

2,661

2,278

5,555

4,739

Amortization of acquired intangibles

—

137

—

274

Non-GAAP gross profit

$

125,817

$

103,268

$

241,837

$

201,182

GAAP gross margin

90.0

%

88.8

%

89.7

%

88.3

%

Non-GAAP gross margin

91.9

%

90.9

%

91.8

%

90.6

%

GAAP research and development expense

$

23,240

$

19,958

$

45,814

$

41,889

Adjusted to exclude the following:

Stock-based compensation

(5,447

)

(2,538

)

(10,131

)

(5,794

)

Non-GAAP research and development expense

$

17,793

$

17,420

$

35,683

$

36,095

GAAP sales and marketing expense

$

34,367

$

30,201

$

69,611

$

64,656

Adjusted to exclude the following:

Stock-based compensation

(6,808

)

(2,697

)

(13,394

)

(8,692

)

Amortization of acquired intangibles

(1,061

)

(1,061

)

(2,122

)

(2,122

)

Change in fair value of contingent earn-out consideration liability

(221

)

(47

)

(423

)

(316

)

Non-GAAP sales and marketing expense

$

26,277

$

26,396

$

53,672

$

53,526

GAAP general and administrative expense

$

10,103

$

8,966

$

19,358

$

18,213

Adjusted to exclude the following:

Stock-based compensation

(2,952

)

(2,288

)

(5,878

)

(4,577

)

Non-GAAP general and administrative expense

$

7,151

$

6,678

$

13,480

$

13,636

GAAP operating expense

$

70,014

$

67,061

$

137,087

$

132,694

Adjusted to exclude the following:

Stock-based compensation

(15,207

)

(7,523

)

(29,403

)

(19,063

)

Amortization of acquired intangibles

(1,061

)

(1,061

)

(2,122

)

(2,122

)

Change in fair value of contingent earn-out consideration liability

(221

)

(47

)

(423

)

(316

)

Restructuring and impairment charge

(2,304

)

(7,936

)

(2,304

)

(7,936

)

Non-GAAP operating expense

$

51,221

$

50,494

$

102,835

$

103,257

GAAP operating income

$

53,142

$

33,792

$

99,195

$

63,475

Adjusted to exclude the following:

Stock-based compensation

17,868

9,801

34,958

23,802

Amortization of acquired intangibles

1,061

1,198

2,122

2,396

Change in fair value of contingent earn-out consideration liability

221

47

423

316

Restructuring and impairment charge

2,304

7,936

2,304

7,936

Non-GAAP operating income

$

74,596

$

52,774

$

139,002

$

97,925

GAAP net income

$

44,154

$

30,602

$

85,531

$

59,008

Adjusted to exclude the following:

Stock-based compensation

17,868

9,801

34,958

23,802

Amortization of acquired intangibles

1,061

1,198

2,122

2,396

Change in fair value of contingent earn-out consideration liability

221

47

423

316

Restructuring and impairment charge

2,304

7,936

2,304

7,936

Income tax effect of non-GAAP adjustments (1)

(4,505

)

(3,986

)

(8,359

)

(7,235

)

Non-GAAP net income

$

61,103

$

45,598

$

116,979

$

86,223

Non-GAAP net income margin

44.7

%

40.1

%

44.4

%

38.8

%

Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

Basic

186,252

193,112

185,933

193,813

Diluted

200,407

209,014

199,818

210,681

Non-GAAP net income per share attributable to Class A and Class B stockholders:

Basic

$

0.33

$

0.24

$

0.63

$

0.44

Diluted

$

0.30

$

0.22

$

0.59

$

0.41

(1) For the three and six months ended September 30, 2024 and 2023, management used an estimated annual effective non-GAAP tax rate of 21.0%.

CT?id=bwnews&sty=20241107362244r1&sid=txguf&distro=ftp

View source version on businesswire.com: https://www.businesswire.com/news/home/20241107362244/en/